Lugano, Switzerland – The European Lung Cancer Congress 2024 is the annual appointment that brings together various experts in the field of thoracic oncology, including thoracic surgeons, respiratory physicians and pneumologists, medical and radiation oncologists, interventional radiologists and pathologists, to discuss the latest insights into the recent developments in the prevention, diagnosis and treatment of lung cancer.
The event will take place in Prague, Czech Republic, and through a dedicated virtual platform between 20-23 March.
Program highlights
- Novel results in the treatment of EGFR-mutant non-small cell lung cancer
Related content: 3MO, 5MO, 8P, 4O - Insights into the opportunities related to the use of immunotherapy, and the challenges related to IO resistance mechanisms that may occur in the treatment of patients with lung cancer
Related content: Sessions on 20 March, 14:30-16:00 CET and 16:30-18:00 CET, session on 21 March, 11:15-12:45 CET - Prevention, screening and early diagnosis of thoracic tumours: from new technologies aimed at improving screening to prevention measures beyond smoking
Related content: Session on 23 March, 10:00-11:30 CET - Emerging evidence on the efficacy and the management of toxicities of antibody-drug conjugates
Related content: 59P, 11P, Session on 23 March, 10:00-11:30 CET
Keynote lecture
- “Advancing precision oncology in lung cancer: A multidisciplinary-driven approach” by Enriqueta Felip, recipient of the Heine H. Hansen Award, 20 March 2024, 13:30-14:15 CET
- “The rise of proteomics in never-smokers in lung cancer” by Yu-Ju Chen, 22 March 2024, 09:30-10:00 CET
- “Incorporating ctDNA and other plasma-based assays into clinical trial design” by Maximilian Diehn, 22 March 2024, 14:30-15:00 CET
The results of more than 240 studies from various parts of the world will be presented and published online as a supplement to ESMO Open. The abstract titles can be viewed through the online program.
Press accreditation
ESMO welcomes press representatives working for recognised press outlets interested in obtaining information and reporting on cancer issues, upon presentation of a letter of assignment and a valid press card. Press representatives are required to observe and abide by the ESMO Policy on Press Activities. To apply for press accreditation, please fill out the form available here. Requests for press accreditation should be sent by Monday, 18 March. Please be kindly informed that onsite press accreditation will not be available.
For further details about the congress, including registration, please click here.
Congress at a glance
When: March 20-23 2024
Venue: Prague Congress Center – 5. května 1640/65, 140 21 Praha 4-Nusle, Czech Republic
About the International Association for the Study of Lung Cancer (IASLC)
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association’s membership includes more than 10,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies.
Contact
Vanessa Pavinato
European Society for Medical Oncology
[email protected]
Office: +41 91 973 55 71